Endometrial stromal sarcoma expression of estrogen receptors, progesterone receptors and estrogen-induced srp27 (24K) suggests hormone responsiveness

Navarro, Domingo; Cabrera, Juan J.; León, Laureano; Chirino, Ricardo; Fernández, Leandro; López, Antonio; Rivero, José Pablo Suárez; Fernández, Porfirio; Falcón, Orlando; Jiménez, Pilar; Pestano, J.; Díaz-Chico, J. C.; Díaz-Chico, B.N.

doi:10.1016/0960-0760(92)90389-z

Cited by 42 publications

(24 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The staining differences among the tumor types were not apparent after use of antigen-retrieval immunohistochemistry methods, which were not used in the three cited reports. The value of ER and cytokeratins in the differential diagnosis of ESS versus uterine smooth muscle tumor is limited, because both ESSs and uterine smooth muscle tumors are usually ER positive and occasionally cytokeratin positive (8,10,11). Inhibin was positive only in cases of ESS with sex-cord-like elements, which can be found in 15 to 60% of ESS (39).…”

Section: Discussionmentioning

confidence: 99%

Utility of CD10 in Distinguishing between Endometrial Stromal Sarcoma and Uterine Smooth Muscle Tumors: An Immunohistochemical Comparison of 34 Cases

et al. 2001

View full text Add to dashboard Cite

Endometrial stromal sarcoma (ESS), uterine cellular leiomyoma (UCL), and uterine leiomyosarcoma (ULS) are composed mainly of spindle cells that express similar antigens such as desmin, smooth muscle actin (SMA), and muscle-specific actin (MSA). The differential diagnosis of an ESS versus a uterine smooth muscle tumor or an extrauterine spindle cell sarcoma can be problematic based solely on clinical presentation, histologic assessment, or routine immunohistochemistry. Recently, we reported that normal endometrium, but not myometrium, as well as five cases of ESS, were positive for CD10. We now report the results of CD10 immunohistochemistry in an additional 11 cases of ESS (total 16 cases), 10 cases of UCL, and nine cases of ULS. CD10 immunoreactivity was detected in 16 of 16 cases of ESS (100%) as compared to only 2 of 10 cases of UCL (20%) and none of nine cases of ULS (0%). We compared the utility of CD10 immunoreactivity with that of desmin, SMA, MSA, estrogen receptor (ER), and inhibin in these tumors. Although the majority of cases of UCL and ULS were positive for SMA, MSA, and desmin, a substantial portion of cases of ESS were also positive for SMA, MSA, and desmin. We conclude that in combination with SMA, MSA, and desmin, CD10 is a useful immunohistochemical marker in the differential diagnosis of ESS versus UCL or ULS.

show abstract

Section: Discussionmentioning

confidence: 99%

Utility of CD10 in Distinguishing between Endometrial Stromal Sarcoma and Uterine Smooth Muscle Tumors: An Immunohistochemical Comparison of 34 Cases

et al. 2001

View full text Add to dashboard Cite

show abstract

“…Oestrogen and progesterone are important regulators of endometrial stromal function and act by binding to their nuclear receptors (Pickartz et al, 1990;Salmi et al, 1998). Most previous studies of sex-steroid receptors in LGSSs were performed biochemically and were based on fewer than five cases of LGSSs (Baker et al, 1984;Lantta et al, 1984;Tsukamoto et al, 1985;Sutton et al, 1986;Katz et al, 1987;Navarro et al, 1992). The reported concentrations of ER in tumour tissue ranged from 0 (Katz et al, 1987) to 1628 (Sutton et al, 1986) and of PR from 0 (Dunton et al, 1990) to 1811 (Dunton et al, 1990) fmol mg -1 cytosol protein.…”

Section: Discussionmentioning

confidence: 99%

Expression of oestrogen and progesterone receptors in low-grade endometrial stromal sarcomas

et al. 2000

View full text Add to dashboard Cite

We analysed oestrogen receptor (ER) and progesterone receptor (PR) expression in a retrospective series of 21 low-grade endometrial stromal sarcomas (LGSSs). Archival formalin-fixed and paraffin-embedded material was analysed by immunohistochemistry. ER and PR were measured with monoclonal antibodies and the peroxidase-antiperoxidase method and a score was calculated as for breast carcinoma based on both the percentage of positive tumour cell nuclei and the staining intensity. ER were seen in 15 (71%) and PR in 20 (95%) of tumours respectively. ER expression was scored as high in three (14%), moderate in four (19%), and low in eight (38%) tumours. Six (29%) tumours did not stain for ER and all of these were positive for PR. PR expression was scored as high in eight (38%), moderate in ten (47%) and weak in two (10%) LGSSs. Only one (5%) LGSS did not stain for PR (this tumour was positive for ER). ER and PR expression in LGSS is heterogeneous. This may have implications for hormone therapy in the management of these tumours. These results suggest that ER and PR should be routinely quantified in LGSSs by immunohistochemical methods. © 2000 Cancer Research Campaign

show abstract

“…Because hormone receptors usually stain uterine smooth muscle tumors, these markers have little reliability in differentiating endometrial stromal tumors from uterine smooth muscle tumors. 9,15,16 Although CD10 is a useful immunohistochemical marker for the differential diagnosis of endometrial stromal sarcomas from uterine cellular leiomyomata, CD10 may also be detected in uterine cellular leiomyomata. 9,11 In this study, we demonstrated that b-catenin nuclear expression is frequently found in endometrial stromal tumors, but not in normal endometrial stroma and uterine cellular leiomyomata.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic use of nuclear Β-catenin expression for the assessment of endometrial stromal tumors

Jung

Lee

et al. 2008

Modern Pathology

View full text Add to dashboard Cite

Alterations in b-catenin degradation cause it to accumulate to immunohistochemically detectable levels in the nuclei of tumor cells. Although it has been shown that nuclear b-catenin immunostaining is useful for the diagnosis of some mesenchymal tumors, there is little known about b-catenin expression in endometrial stromal tumors. In this study, nuclear b-catenin immunoreactivity was evaluated in normal endometrium and endometrial mesenchymal tumors and then compared with that of CD10. The endometrial mesenchymal tumors evaluated included endometrial stromal nodules (n ¼ 2), low-grade endometrial stromal sarcomas (n ¼ 12), undifferentiated endometrial sarcomas (n ¼ 8) and uterine cellular leiomyomata (n ¼ 9). In addition, direct DNA sequencing of b-catenin exon 3 was conducted in 15 endometrial stromal tumors. Normal endometrial stromal cells showed strong cytoplasmic reactivity for CD10 but no detectable reactivity for b-catenin. Nuclear b-catenin immunoreactivity was detected in 11 low-grade endometrial stromal sarcomas (92%) and 6 undifferentiated endometrial sarcomas (75%). Ten low-grade endometrial stromal sarcomas (83%) and six undifferentiated endometrial sarcomas (75%) were positive for CD10. Eight low-grade endometrial stromal sarcomas (67%) exhibited diffuse, strong nuclear immunoreactivity with b-catenin, whereas only four cases (33%) expressed diffuse, strong immunoreactivity with CD10. All nine cases of uterine cellular leiomyomata were completely negative for both CD10 and b-catenin. b-catenin mutations were rare in endometrial stromal tumors. Taken together, these results indicate that nuclear b-catenin immunostaining can serve as a sensitive immunohistochemical marker for the diagnosis of endometrial stromal tumors and is useful for differentiating low-grade endometrial stromal sarcomas from uterine cellular leiomyomata.

show abstract

Endometrial stromal sarcoma expression of estrogen receptors, progesterone receptors and estrogen-induced srp27 (24K) suggests hormone responsiveness

Cited by 42 publications

References 19 publications

Utility of CD10 in Distinguishing between Endometrial Stromal Sarcoma and Uterine Smooth Muscle Tumors: An Immunohistochemical Comparison of 34 Cases

Utility of CD10 in Distinguishing between Endometrial Stromal Sarcoma and Uterine Smooth Muscle Tumors: An Immunohistochemical Comparison of 34 Cases

Expression of oestrogen and progesterone receptors in low-grade endometrial stromal sarcomas

Diagnostic use of nuclear Β-catenin expression for the assessment of endometrial stromal tumors

Contact Info

Product

Resources

About